Mutational Analysis of PRKAR1A and Gsα in Sporadic Adrenocortical Tumors

Abstract

Little is known about the pathogenesis of adrenocortical tumors. The cAMP-dependent pathway is physiologically activated by ACTH in adrenocortical cells and different components of this cascade may be altered in some functioning adrenocortical tumors. Recently, mutations of the gene encoding the PKA type 1 A regulatory subunit (R1 A), PRKAR1A, associated with loss of heterozygosity (LOH) at PRKAR1A locus, have been demonstrated in primary pigmented nodular adrenocortical disease (PPNAD), either isolated or associated with Carney complex. Moreover, activating mutations of the Gsα gene (the gsp oncogene) have also been found in a small number of adrenocortical cortisol-secreting adenomas. Aim of this study was to investigate the presence of such genetic alterations on a series of 10 ACTH-independent Cushing syndrome due to non-PPNAD adrenocortical adenomas. The coding sequence of PRKAR1A, evaluated by PCR and direct sequencing analysis, revealed the absence of mutations while heterozygosity for at least 1 polymorphism excluded LOH in most tumors. In one single adenoma gsp mutation was detected. In conclusion, we provide additional evidence that the only mutational changes able to activate the cAMP pathway so far identified, i.e. PRKAR1A mutations and gsp oncogene, are a rare event in adrenocortical tumors.

Key words

Adrenocortical tumors - PKAR1A - Gsα

References

• 1 Ballare E, Mantovani S, Lania A, Di Blasio A M, Vallar L, Spada A. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors.  J Clin Endocrinol Metab. 1998;  83 4386-4390
• 2 Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgioo T, Bourdeau I, Kirschner L S, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis C A. Molecular and functional analysis of PRKAR1A and its locus (17 q22 - 24) in sporadic adrenocortical tumors: 17 q losses, somatic mutations, and protein kinase A expression and activity.  Canc Res. 2003;  63 5308-5319
• 3 Casey M, Vaughan C J, He J, Hatcher C J, Winter J M, Weremowicz S, Montgomery K, Kucherlapati R, Morton C C, Basson C T. Mutations in the protein kinase A R1alpha regulatory subunit cause familial myxomas and Carney complex.  J Clin Invest. 2000;  106 R31-R38
• 4 Fragoso M C, Domenice S, Latronico A C, Martin R M, Pereira M A, Zerbini M C, Lucon A M, Mendonca B B. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene.  J Clin Endocrinol Metab. 2003;  885 2147-2151
• 5 Kaltsas G A, Kola B, Borboli N, Morris D G, Gueorguiev M, Swords F M, Czirjak S, Kirschner L S, Stratakis C A, Korbonits M, Grossman A B. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours.  Clin Endocrinol. 2002;  57 443-448
• 6 Kirschner L S, Carney J A, Pack S D, Taymans S E, Giatzakis C, Cho Y S, Cho-Chung Y S, Stratakis C A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.  Nat Genet. 2000 a;  26 89-92
• 7 Kirschner L S, Sandrini F, Monbo J, Lin J P, Carney J A, Stratakis C A. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex.  Hum Mol Genet. 2000 b;  9 3037-3046
• 8 Kobayashi H, Usui T, Fukata J, Yoshimasa T, Oki Y, Nakao K. Mutation analysis of Gs alpha, adrenocorticotropin receptor and p53 genes in patients with adrenocortical neoplasms: including a case of Gs alpha mutation.  Endocr J. 2000;  47 461-466
• 9 Lieberman S A, Eccleshall T R, Feldman D. ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome.  Eur J Endocrinol. 1994;  131 67-73
• 10 Lionel G, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton J P, Bertagna X, Bertherat J. Mutations of the PRKAR1A gene in Cushing's sindrome due to sporadic primary pigmented nodular adrenocortical disease.  J Clin Endocrinol Metab. 2002;  87 4324-4329
• 11 Mantovani G, Romoli R, Weber G, Brunelli V, De Menis E, Beccio S, Beck-Peccoz P, Spada A. Mutational analysis of GNAS1 in patients with pseudohypoparathyroidism: identification of two novel mutations.  J Clin Endocrinol Metab. 2000;  85 4243-4248
• 12 Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The Gsα gene: predominant maternal origin of transcription in human thyroid gland and gonads.  J Clin Endocrinol Metab. 2002;  87 4736-4740
• 13 Sandrini F, Kirschner L S, Bei T, Farmakidis C, Yasufuku-Takano J, Takano K, Prezant T R, Marx S J, Farrel W E, Clayton R N, Groussin L, Bertherat J, Stratakis C A. PRKAR1A, one of the Carney complex genes, and its locus (17 q22 - 24) are rarely altered in pituitary tumours outside the Carney complex.  J Med Genet. 2002;  39 e78
• 14 Sandrini F, Stratakis C A. Clinical and molecular genetics of Carney complex.  Mol Genet Metab. 2003;  78 83-92
• 15 Sarlis N J, Chrousos J P, Doppman J L, Carney J A, Stratakis C A. Primary pigmented nodular adrenocortical disease: reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy.  J Clin Endocrinol Metab. 1997;  82 1274-1278
• 16 Stratakis C A, Sarlis N, Kirschner L S, Carney J A, Doppman J L, Nieman L K, Chrousos G P, Papanicolaou D A. Paradoxical response to dexamethasone in the diagnosis of primari pigmented nodular adrenocortical disease.  Ann Intern Med. 1999;  131 585-591
• 17 Stratakis C A, Kirschner L S, Carney J A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.  J Clin Endocrinol Metab. 2001;  86 4041-4046
• 18 Travis W D, Tsokos M, Doppman J L, Nieman L, Chrousos G P, Cutler Jr G B, Loriaux D L, Norton J A. Primary pigmented nodular adrenocortical disease. A light and electron microscopic study of eight cases.  Am J Surg Pathol. 1989;  13 921-930
• 19 Weinstein L S, Shenker A, Gejman P, Marino M J, Friedman E, Spiegel A M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.  New Engl J Med. 1991;  325 1688-1695
• 20 Yamasaki H, Mizusawa N, Nagahiro S, Yamada S, Sano T, Itakura M, Yoshimoto K. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17 q23 - 24.  Clin Endocrinol. 2003;  58 464-470

1 These two authors contributed equally to this work and are considered as first co-authors